Long-term survival outcomes with Nivolumab (Nivo) in patients with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response

被引：0
|
作者：
Wohlleber, M. [1 ]
Brahmer, J. [2 ]
Borghaei, H. [3 ]
Ramalingam, S. S. [4 ]
Horn, L. [5 ]
de Castro Carpeno, J. [6 ]
Pluzanski, A. [7 ]
Burgio, M. A. [8 ]
Garassino, M. [9 ]
Chow, L. Q. M. [10 ]
Gettinger, S. [11 ]
Crino, L. [7 ]
Planchard, D. [12 ]
Butts, C. [13 ]
Drilon, A. [14 ]
Wojcik-Tomaszewska, J. [15 ]
Otterson, G. [16 ]
Agrawal, S. [17 ]
Li, A. [17 ]
Penrod, J. R. [17 ]
Antonia, S. J. [18 ]
机构：
[1] Robert Bosch Ctr Tumorerkankungen RBCT, Dept Pneumol Oncol, Gerlingen, Germany
[2] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[6] Ctr Integral Oncol Clara Campal, Madrid, Spain
[7] Inst Marii Sklodowskiej Curie, Ctr Onkol, Klin Nowotworow Pluca & Klatki Piersiowej, Warsaw, Poland
[8] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCSS, Med Oncol Unit, Meldola, Italy
[9] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[10] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA
[11] Yale Canc Ctr, New Haven, CT USA
[12] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France
[13] Cross Canc Inst, Dept Oncol, Div Med Oncol, Edmonton, AB, Canada
[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[15] Wojewodzkie Ctr Onkol, Gdansk, Poland
[16] Ohio State Univ, Columbus, OH 43210 USA
[17] Bristol Myers Squibb, Princeton, NJ USA
[18] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P406
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [21] Patterns of Response to Nivolumab in Patients with Non-Small Cell Lung Cancer (NSCLC)
    Schmid, S.
    Diem, S.
    Krapf, M.
    Li, Q.
    Flatz, L.
    Leschka, S.
    Desbiolles, L.
    Klingbiel, D.
    Jochum, W.
    Fruh, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2419 - S2420
  • [22] ERLOTINIB AND BEXAROTENE FOR PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Dragnev, K. H.
    Seltzer, M.
    Rigas, J. R.
    DiSalvo, W. M.
    Simeone, S.
    Johnstone, D.
    Nugent, W.
    Waxman, S.
    Dmitrovsky, E.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 102 - 102
  • [23] Factors associated with long-term survival of patients with advanced non-small cell lung cancer
    Leprieur, Etienne Giroux
    Lavole, Armelle
    Ruppert, Anne-Marie
    Gounant, Valerie
    Wislez, Marie
    Cadranel, Jacques
    Milleron, Bernard
    [J]. RESPIROLOGY, 2012, 17 (01) : 134 - 142
  • [24] Long-term survival in patients with non-small cell lung cancer treated with palliative radiotherapy
    Quddus, AMMZ
    Kerr, GR
    Price, A
    Gregor, A
    [J]. CLINICAL ONCOLOGY, 2001, 13 (02) : 95 - 98
  • [25] Analysis of long-term survival in patients with locally advanced non-small cell lung cancer
    Wagner, W
    Striehn, E
    Klinke, F
    Bosse, U
    Rube, C
    [J]. ONCOLOGY REPORTS, 1998, 5 (06) : 1547 - 1550
  • [26] Evaluation of disease-related symptoms in patients (pts) with advanced squamous (SQ) non-small cell lung cancer (NSCLC) treated with nivolumab (NIVO) or docetaxel (DOC)
    Gralla, R. J.
    Coon, C.
    Taylor, F.
    Penrod, J. R.
    DeRosa, M.
    Dastani, H.
    Orsini, L.
    Reck, M.
    [J]. Oncology Research and Treatment, 2015, 38 : 14 - +
  • [27] Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
    Ricciuti, Biagio
    Genova, Carlo
    De Giglio, Andrea
    Bassanelli, Maria
    Dal Bello, Maria Giovanna
    Metro, Giulio
    Brambilla, Marta
    Baglivo, Sara
    Grossi, Francesco
    Chiari, Rita
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (02) : 479 - 485
  • [28] Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis
    Biagio Ricciuti
    Carlo Genova
    Andrea De Giglio
    Maria Bassanelli
    Maria Giovanna Dal Bello
    Giulio Metro
    Marta Brambilla
    Sara Baglivo
    Francesco Grossi
    Rita Chiari
    [J]. Journal of Cancer Research and Clinical Oncology, 2019, 145 : 479 - 485
  • [29] Long-term survival of patients with advanced non-small cell lung cancer treated using immune checkpoint inhibitors
    Tamiya, Akihiro
    [J]. RESPIRATORY INVESTIGATION, 2024, 62 (01) : 85 - 89
  • [30] Nivolumab Versus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer and Liver Metastases
    Crino, L.
    Horn, L.
    Felip, E.
    Frontera, O. Aren
    Burgio, M.
    Waterhouse, D.
    Blumenschein, G.
    Barlesi, F.
    Garassino, M.
    Holgado, E.
    Antonia, S.
    Spigel, D.
    Gainor, J.
    Gettinger, S.
    Geese, W.
    Li, A.
    Healey, D.
    Ready, N.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2302 - S2302
12345